Insider Trading Alert - USCR, BSTC And OCN Traded By Insiders

Yesterday, Nov. 24, 2015, 106 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $189.51 to $48,391,506.50.

Highlighted Stocks Traded by Insiders:

US Concrete (USCR) - FREE Research Report

Sutherland Colin McGill, who is Director at US Concrete, sold 4,000 shares at $59.09 on Nov. 24, 2015. Following this transaction, the Director owned 14,787 shares meaning that the stake was reduced by 21.29% with the 4,000-share transaction.

The shares most recently traded at $60.45, up $1.36, or 2.24% since the insider transaction. Historical insider transactions for US Concrete go as follows:

  • 4-Week # shares bought: 1,000
  • 4-Week # shares sold: 6,500
  • 12-Week # shares bought: 1,000
  • 12-Week # shares sold: 27,732
  • 24-Week # shares bought: 1,000
  • 24-Week # shares sold: 40,826

The average volume for US Concrete has been 200,100 shares per day over the past 30 days. US Concrete has a market cap of $877.1 million and is part of the industrial goods sector and materials & construction industry. Shares are up 112.37% year-to-date as of the close of trading on Tuesday.

U.S. Concrete, Inc., through its subsidiaries, produces and sells ready-mixed concrete, aggregates, and concrete-related products and services for the construction industry in the United States. It operates through two segments, Ready-Mixed Concrete and Aggregate Products. The company has a P/E ratio of 285.0. Currently, there are 2 analysts who rate US Concrete a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on USCR - FREE

TheStreet Quant Ratings rates US Concrete as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, generally higher debt management risk and disappointing return on equity. Get the full US Concrete Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

BioSpecifics Technologies (BSTC) - FREE Research Report

Wegman Thomas, who is President & CEO at BioSpecifics Technologies, sold 14,000 shares at $50.09 on Nov. 24, 2015. Following this transaction, the President & CEO owned 122,822 shares meaning that the stake was reduced by 10.23% with the 14,000-share transaction.

The shares most recently traded at $48.80, down $1.29, or 2.64% since the insider transaction. Historical insider transactions for BioSpecifics Technologies go as follows:

  • 4-Week # shares sold: 38,000
  • 12-Week # shares sold: 38,000
  • 24-Week # shares sold: 38,000

The average volume for BioSpecifics Technologies has been 78,200 shares per day over the past 30 days. BioSpecifics Technologies has a market cap of $340.7 million and is part of the health care sector and drugs industry. Shares are up 26.83% year-to-date as of the close of trading on Tuesday.

BioSpecifics Technologies Corp., a biopharmaceutical company, engages in the development of an injectable collagenase clostridium histolyticum for multiple indications in the United States. The company has a P/E ratio of 40.0. Currently, there are no analysts who rate BioSpecifics Technologies a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on BSTC - FREE

TheStreet Quant Ratings rates BioSpecifics Technologies as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and compelling growth in net income. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full BioSpecifics Technologies Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Ocwen Financial (OCN) - FREE Research Report

Hayes Timothy M., who is EVP, Gen. Counsel & Secretary at Ocwen Financial, bought 2,000 shares at $6.46 on Nov. 24, 2015. Following this transaction, the EVP, Gen. Counsel & Secretary owned 18,000 shares meaning that the stake was boosted by 12.5% with the 2,000-share transaction.

The shares most recently traded at $6.52, up $0.06, or 0.95% since the insider transaction. Historical insider transactions for Ocwen Financial go as follows:

  • 4-Week # shares bought: 5,000
  • 12-Week # shares bought: 5,000
  • 24-Week # shares bought: 5,000
  • 24-Week # shares sold: 2,000

The average volume for Ocwen Financial has been 2.2 million shares per day over the past 30 days. Ocwen Financial has a market cap of $812.5 million and is part of the financial sector and real estate industry. Shares are down 57.55% year-to-date as of the close of trading on Tuesday.

Ocwen Financial Corporation, a financial services holding company, engages in servicing and origination of mortgage loans in the United States. Currently, there are no analysts who rate Ocwen Financial a buy, 1 analyst rates it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on OCN - FREE

TheStreet Quant Ratings rates Ocwen Financial as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full Ocwen Financial Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Nutrisystem Soars on Deal to Be Acquired by Tivity Health

Nutrisystem Soars on Deal to Be Acquired by Tivity Health

Economist Perspective: Can U.S. Dollar Keep Its Momentum in 2019?

Economist Perspective: Can U.S. Dollar Keep Its Momentum in 2019?

Monday Madness: Apple's Looking Pretty Bruised

Monday Madness: Apple's Looking Pretty Bruised

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

Stocks End Day in the Green as Dow, S&P Overcome Slow Starts

These Bank Stocks Could Be Oversold in the Market Wreckage

These Bank Stocks Could Be Oversold in the Market Wreckage